Perspective Therapeutics Inc CATX

$0.94 +0.10 (11.95%)

Valuation

Market cap
101,727,000
Revenue TTM
$880,000
Net income TTM
$-103,120,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
-11,718.18%
Debt to equity
0.00

Trading

Volume
3,184,400
Avg volume
3,088,214
Day's range
$0.85 – $0.97
Shares out
120,759,000
Stochastic %K
55%
Beta
2.02
Analysts
Strong Buy
Price target
$9.71

Price

Company profile

Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previous...

Show more

Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; and PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha. The company also develops Pluvicto, a betaemitting radioligand therapy to treat progressive prostate-specific membrane antigen (PSMA) positive metastatic castration-resistant prostate cancer. It has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 2004 and is headquartered in Seattle, Washington.

Industry
Medical Devices
Sector
Healthcare
Phone
206 676 0900
Website
https://www.perspectivetherapeutics.com
Address
2401 Elliott Avenue, Suite 320, Seattle, United States

Latest news

Stocktwits

Biotechs2027 Nov 14, 12:51 AM
Perspective Therapeutics CMO Markus Puhlmann buys $34,544 in stock By Investing.com $CATX https://www.investing.com/news/insider-trading-news/perspective-therapeutics-cmo-markus-puhlmann-buys-34544-in-stock-93CH-5025607
0 replies
topstockalerts Nov 14, 12:00 AM
$CATX buyers are treating weakness like an opportunity.
0 replies
JDinvestments Nov 13, 8:00 PM
$CATX our manufacturing is worth more than $1 Shortfall of most in This industry STRONG BUYOUT 💰💰💰🚀🚀🚀🚀🚀🚀🥂🥂🥂
1 replies
Biotechs2027 Nov 13, 6:12 PM
Making a U type recovery. $2.00 incoming $CATX
0 replies
naudz Nov 13, 4:39 PM
$CATX • Cash & Short-Term Investments. Approximately $202.0 million (as of September 30, 2026). • Shares Outstanding. Approximately 120.76 million common shares. • Cash Per Share. $1.67 per share ($202.0M ÷ 120.76M shares). • Current Stock Price. $0.9476 per share (representing a $114.76 million market cap). • Price-to-Cash Ratio. 0.57x ($0.9476 ÷ $1.6728).
0 replies
MartellSteez Nov 13, 4:36 PM
$CATX I'm gonna have to lump in to get my money back 😂
0 replies
mittj Nov 13, 4:36 PM
$CATX my guess is that by end of December we ar between 2,50-4$
0 replies
naudz Nov 13, 4:36 PM
$CATX i smel in 2 weeks 2$
0 replies